News Release



April 29, 2015

Ashland Inc. reports preliminary financial results for second quarter of fiscal 2015

- Earnings from continuing operations total \$1.39 per diluted share
- Adjusted earnings from continuing operations grow 33 percent, to \$2.03 per diluted share
- Adjusted EBITDA rises nearly 11 percent, to \$301 million; adjusted EBITDA margin climbs 470 basis points to 22.3 percent
- Substantially all of the \$200 million in annual run-rate savings from global restructuring now captured
- Board approves new \$1 billion share repurchase authorization

COVINGTON, Ky. – Ashland Inc. (NYSE: ASH), a global leader in specialty chemical solutions for consumer and industrial markets, today announced preliminary⁽¹⁾ financial results for the fiscal second quarter ended March 31, 2015.

Quarterly Highlights

(in millions except per-share amounts)	(Quarter Er	nded M	1ar. 31
		2015	_	2014
Operating income (loss)	\$	193	\$	(64)
Key items*		25		247
Adjusted operating income*	\$	218	\$	183
Adjusted EBITDA*	\$	301	\$	272
Diluted earnings (loss) per share				
From net income	\$	3.26	\$	(0.57)
From continuing operations	\$	1.39	\$	(0.78)
Key items*		0.64		2.31
Adjusted EPS from continuing operations*	\$	2.03	\$	1.53
Cash flows provided by operating activities from continuing operations	\$	47	\$	175
Free cash flow*		4		124
* See Tables 5, 6 and 7 for Ashland definitions and U.S. GA reconciliations.	AP			

Ashland reported earnings from continuing operations of \$95 million, or \$1.39 per diluted share, on sales of \$1.35 billion. These results included five key items that together

reduced income from continuing operations by approximately \$43 million, net of tax, or \$0.64 per diluted share. Excluding the five key items, Ashland's adjusted income from continuing operations was \$138 million, or \$2.03 per diluted share. (Please refer to Table 5 of the accompanying financial statements for details of key items.)

For the year-ago quarter, Ashland reported a loss from continuing operations of \$61 million, or \$0.78 per diluted share, on sales of \$1.5 billion. There were five key items in the year-ago quarter that, on a combined basis, reduced income from continuing operations by \$181 million after tax, or \$2.31 per share. Excluding those five items, Ashland's adjusted income from continuing operations was \$120 million, or \$1.53 per share.

For the remainder of this news release, financial results have been adjusted to exclude the effect of key items in both the current and prior-year quarters. On this basis, Ashland's results as compared to the year-ago quarter were as follows:

- Sales revenue fell 13 percent, largely as a result of divestitures and foreign exchange rates; excluding these headwinds, sales declined 3 percent;
- Despite this revenue decline, mix improvements resulted in profit growth;
- Selling, general and administrative (SG&A) costs declined 9 percent, to \$239 million, as a result of the global restructuring and foreign exchange;
- Operating income grew 19 percent to \$218 million;
- Earnings before interest, taxes, depreciation and amortization (EBITDA) increased nearly 11 percent to \$301 million; and
- EBITDA as a percent of sales increased 470 basis points to 22.3 percent.

"Since I joined the Ashland team in January, we have focused on three core priorities," said William A. Wulfsohn, Ashland chairman and chief executive officer. "Our first priority has been to deliver our near- and mid-term financial targets. In the quarter, the Ashland team continued to execute at a high level as is evidenced by our solid earnings and margin growth. Ashland's strong EBITDA growth was driven by aggressive cost control, by taking focused actions to improve sales mix and by maintaining a disciplined approach to pricing in the context of considerable input cost volatility. After much difficult work over the past year, the team has now captured substantially all of the expected \$200 million in annualized run-rate cost savings from the global restructuring program."

He added: "Our second core priority has been to continue the journey to reposition our portfolio to focus on the core segments where Ashland delivers highly differentiated, value-added products to customers."

As examples, he pointed to Ashland Specialty Ingredients, where higher-margin pharmaceutical and hair-care lines grew volume by 7 percent and 12 percent, respectively. Meanwhile, Ashland Performance Materials reported another quarter of good volume growth in composites, including unique products such as DerakaneTM epoxy vinyl ester resin. At Valvoline, continued growth in premium-brand lubricant sales, store expansion at Valvoline Instant Oil ChangeSM and lower raw-material costs helped drive record profits.

Wulfsohn said Ashland's third core priority, given its strong balance sheet, has been to effectively allocate capital through targeted investments in organic growth opportunities and through share repurchases. For example, the company recently announced an

important capacity expansion at its manufacturing facility in Hopewell, Virginia, to support increased demand from customers in the high-growth personal care and coatings end markets, where Specialty Ingredients' products add considerable value. In addition, Ashland continued to return cash to shareholders in the second quarter through its previously announced \$270 million accelerated stock repurchase (ASR) program. The company received 1.9 million shares up front and expects to receive the remaining shares prior to the program's expiration on July 31, 2015. Upon completion of the ASR, Ashland will have finished its previously announced \$1.35 billion share repurchase authorization. As a result, Ashland today announced that its board has approved a new \$1 billion authorization that expires December 31, 2017.

"This new stock repurchase authorization reflects the board's continued confidence in Ashland's strategic direction and the cash-generating capabilities of the assets," Wulfsohn said. "At this time, we believe Ashland stock remains undervalued and represents an attractive investment opportunity."

Business Segment Performance

To aid understanding of Ashland's ongoing business performance, the results of Ashland's business segments are described below on an adjusted basis and EBITDA, or adjusted EBITDA, is reconciled to operating income in Table 7 of this news release.

Within Specialty Ingredients, improved business and product mix, as well as continued strong cost discipline, led to a 9 percent increase in EBITDA, to \$142 million. EBITDA margin increased 370 basis points, to 24.4 percent. Savings from the global restructuring program contributed to a 10 percent decline in SG&A expenses. Overall sales declined 7 percent, to \$583 million, primarily due to currency headwinds, weak energy markets and exited product lines. Within consumer, Ashland's sales grew a currency-adjusted 2 percent as good demand for Ashland's patented oral- and hair-care applications was partially offset by weakness in skin care. Pharmaceutical volumes grew 7 percent. On the industrial side, excluding energy, overall volumes were flat and currency-adjusted sales fell 1 percent. However, adhesives posted another good quarter, with volumes increasing 2 percent from prior year. In addition, we continue to see increased demand within the coatings market, where volume grew 2 percent, primarily due to the completion in late February of the first phase of expansion at our hydroxyethylcellulose (HEC) facility in Nanjing, China.

Looking ahead to the fiscal third quarter, Specialty Ingredients expects continued growth in the high-value-add, higher-margin areas of the business. However, the commercial unit expects to face headwinds from currency, continued weakness in energy markets and exited product lines. Specialty Ingredients expects third-quarter sales to be in the range of \$600-\$620 million. Continued mix improvement, higher margins and cost discipline should lead to estimated EBITDA margin of 24-24.5 percent.

At Performance Materials, good growth in composites volume, combined with lower input and manufacturing costs, helped drive a 350-basis-point increase in EBITDA margin, to 15.4 percent. It is important to note that the prior-year quarter included a combined \$13 million in EBITDA from the elastomers division and the ASK Chemicals joint venture that were divested later in the year. Sales declined 31 percent, to \$286 million, as a result of divestitures, currency headwinds and lower butanediol (BDO) volume and pricing within intermediates and solvents (I&S). Adjusting for these factors, sales declined 5 percent. Composites volume grew in most major regions of the world,

including Europe, where the company is beginning to see signs of improvement. I&S sales declined from prior year due to lower volumes, softer butanediol pricing and currency headwinds.

Looking to the fiscal third quarter, Performance Materials expects to see continued growth in composites volume, although some margin compression is likely due to rising raw-material costs in some regions. In addition, the combination of declining BDO prices, a planned turnaround at one of Ashland's I&S plants, and an unplanned shutdown at another I&S plant, is expected to reduce EBITDA margin in the third quarter.

Valvoline turned in a strong performance as improved mix and lower raw-material costs led to higher profitability and margins in the second quarter. EBITDA rose 18 percent, to \$106 million, and EBITDA as a percent of sales was 22.0 percent, an increase of 410 basis points versus the prior year. Although three of Valvoline's four channels to market reported year-over-year volume gains, total sales declined 4 percent, to \$481 million, primarily as a result of currency headwinds. Successful promotions drove volume growth in Do-it-Yourself (DIY). Valvoline Instant Oil Change (VIOC) reported same-store sales growth of nearly 7 percent at company-owned sites. Across the broader VIOC network, the total number of oil changes rose 7 percent, with 9 percent growth in premium oil changes. Within Valvoline's international channel, growth appeared to return as distributor destocking issues abated. Both volume and currency-adjusted sales in the international channel rose 2 percent. On a global basis, Valvoline's overall mix continued to improve, with premium-branded lubricant sales volume increasing to 40.7 percent from 37.1 percent a year ago.

Earlier this month, Ashland agreed to sell Valvoline's car-care products assets to Highlander Capital LLP. These assets include brands such as Car Brite[™], Eagle One[™] and Pyroil[™]. Also included in the sale are Valvoline-branded and private-label maintenance chemicals sold into the DIY channel. Proceeds from the sale of this non-strategic asset will be reinvested in generating more rapid, profitable growth within Valvoline's core lubricants business, such as through the continued expansion of the VIOC store base.

For the third quarter, Valvoline expects to continue benefitting from strong promotions across its U.S. channels as the summer driving season approaches. Good product and business mix should drive strong margins, although continued price adjustments will likely offset some of that strength.

Ashland's adjusted effective tax rate for the March 2015 quarter was 21 percent, or 300 basis points below the low end of our previous guidance due to discrete tax adjustments in the quarter. Ashland continues to expect its effective tax rate for fiscal 2015 to be in the range of 24-26 percent.

Asbestos Insurance Settlement

In January 2015, Ashland entered into a settlement agreement concerning certain insurance coverage for asbestos bodily injury claims. The company received \$398 million in cash. As a result of the settlement agreement, Ashland recorded an after-tax gain of \$120 million within discontinued operations. In addition, Ashland placed \$335 million of the settlement funds received into a renewable annual trust restricted for the purpose of paying for ongoing and future litigation defense and claim settlement costs incurred in conjunction with asbestos claims.

Looking Ahead

As Ashland enters the second half of fiscal 2015, Wulfsohn said he is pleased with the company's progress.

"Ashland's performance through the first half of the fiscal year is the result of sound execution. Looking forward, we will continue to focus on cost control and prioritizing highly profitable, differentiated growth segments while sustaining effective capital allocation. We are playing to our strengths by focusing on the products and markets where we provide the most value to our customers. We continue to make incremental capital investments to expand product manufacturing capacity for some high-growth end markets. We also have divested less strategic segments, such as Valvoline's car-care products assets. We are pleased to have board authorization to continue our stock repurchase program as we believe this is currently the best use of our strong balance sheet and cash flow," Wulfsohn said.

Conference Call Webcast

Ashland will host a live webcast of its second-quarter conference call with securities analysts at 9 a.m. EDT Thursday, April 30, 2015. The webcast and supporting materials will be accessible through Ashland's website at http://investor.ashland.com. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.

Use of Non-GAAP Measures

This news release includes certain non-GAAP (Generally Accepted Accounting Principles) measures. Such measurements are not prepared in accordance with GAAP and should not be construed as an alternative to reported results determined in accordance with GAAP. Management believes the use of such non-GAAP measures assists investors in understanding the ongoing operating performance of the company and its segments. The non-GAAP information provided may not be consistent with the methodologies used by other companies. All non-GAAP amounts have been reconciled with reported GAAP results in Tables 5, 6 and 7 of the financial statements provided with this news release.

About Ashland

Ashland Inc. (NYSE: ASH) is a global leader in providing specialty chemical solutions to customers in a wide range of consumer and industrial markets, including architectural coatings, automotive, construction, energy, food and beverage, personal care and pharmaceutical. Through our three commercial units – Ashland Specialty Ingredients, Ashland Performance Materials and Valvoline – we use good chemistry to make great things happen for customers in more than 100 countries. Visit <u>ashland.com</u> to learn more.

- 0 -

C-ASH

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "may," "will," "should" and "intends" and

the negative of these words or other comparable terminology. In addition, Ashland may from time to time make forward-looking statements in its annual report, guarterly reports and other filings with the Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance and financial condition, the economy and other future events or circumstances. Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); the global restructuring program (including the possibility that Ashland may not achieve the anticipated revenue and earnings growth, cost reductions, and other expected benefits from the program), Ashland's ability to generate sufficient cash to finance its stock repurchase plans, severe weather, natural disasters, and legal proceedings and claims (including environmental and asbestos matters). Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including, without limitation, risks and uncertainties affecting Ashland that are described in its most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at www.sec.gov. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

⁽¹⁾ Preliminary Results

Financial results are preliminary until Ashland's Form 10-Q is filed with the SEC.

SM Service mark, Ashland or its subsidiaries, registered in various countries. [™] Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Jason Thompson +1 (859) 815-3527 <u>ilthompson@ashland.com</u>

Media Relations: Gary Rhodes +1 (859) 815-3047 <u>glrhodes@ashland.com</u>

Ashland Inc. and Consolidated Subsidiaries STATEMENTS OF CONSOLIDATED INCOME

(In millions except per share data - preliminary and unaudited)

	Three months end March 31				Ma			
		2015		2014		2015		2014
Sales	\$	1,350	\$	1,545	\$	2,741	\$	2,977
Cost of sales		925		1,168		1,906		2,216
GROSS PROFIT		425		377		835		761
Selling, general and administrative expense		203		370		429		605
Research and development expense		25		36		50		63
Equity and other income (loss)		(4)		(35)		6		(14)
OPERATING INCOME (LOSS)		193		(64)		362		79
Net interest and other financing expense		40		41		81		83
Net gain (loss) on divestitures		(33)		1		(118)		6
INCOME (LOSS) FROM CONTINUING OPERATIONS								
BEFORE INCOME TAXES		120		(104)		163		2
Income tax expense (benefit)		25		(43)		27		(25)
INCOME (LOSS) FROM CONTINUING OPERATIONS		95		(61)		136		27
Income from discontinued operations (net of taxes)		129		17		121		39
NET INCOME (LOSS)	\$	224	\$	(44)	\$	257	\$	66
DILUTED EARNINGS PER SHARE								
Income (loss) from continuing operations	\$	1.39	\$	(0.78)	\$	1.95	\$	0.35
Income from discontinued operations		1.87		0.21		1.73		0.49
Net income (loss)	\$	3.26	\$	(0.57)	\$	3.68	\$	0.84
AVERAGE COMMON SHARES AND ASSUMED CONVERSIONS		69		78		70		79
SALES								
Specialty Ingredients	\$	583	\$	629	\$	1,144	\$	1,209
Performance Materials		286		413		623		779
Valvoline		481		503		974		989
	\$	1,350	\$	1,545	\$	2,741	\$	2,977
OPERATING INCOME (LOSS)								
Specialty Ingredients	\$	65	\$	61	\$	125	\$	113
Performance Materials	Ŧ	30	Ŧ	(35)	Ŧ	55	T	(22)
Valvoline		82		81		165		156
Unallocated and other		16		(171)		17		(168)
	\$	193	\$	(64)	\$	362	\$	79

Ashland Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions - preliminary and unaudited)

ASSETS Current assets \$ 911 \$ 1,393 Accounts receivable 1,046 1,202 Inventories 714 765 Deferred income taxes 110 83 Total current assets 2,902 3,561 Noncurrent assets 2,902 3,561 Noncurrent assets 2,902 3,561 Noncurrent assets 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Assets insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total anocurrent assets 501 510 Current liabilities 508 675 Short-term debt 9 9 Current liabilities 508 675 Total assets 508 675 Noncurrent liabilities 508 675 Noncurrent liabilities <th></th> <th>Ma</th> <th colspan="2">March 31 2015</th> <th>tember 30 2014</th>		Ma	March 31 2015		tember 30 2014
Cash and cash equivalents \$ 911 \$ 1,393 Accounts receivable 1,046 1,202 Inventories 714 765 Deferred income taxes 121 118 Other assets 2,902 3,561 Noncurrent assets 2,902 3,561 Noncurrent assets 2,902 3,561 Noncurrent assets 2,063 2,414 Goodwill 2,463 2,463 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 69 81 Other assets 501 510 Total noncurrent assets 69 81 Other assets 500 674 Accrued expenses and other liabilities 508 675 Total current liabilities 508 675 Total current liabilities 508 675 Total assets 508 675 Total assets 508 675 Total assets 508 675 <th>ASSETS</th> <th></th> <th></th> <th></th> <th></th>	ASSETS				
Accounts receivable 1,046 1,202 Inventories 714 765 Deferred income taxes 121 118 Other assets 2,902 3,561 Noncurrent assets 2,902 3,561 Noncurrent assets 2,902 3,561 Property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbesto insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total assets 501 510 Current labilities 508 675 Short-term debt 9 9 Current payables 500 674 Accrued expenses and other liabilities 508 675 Total current liabilities 508 675 Total current liabilities 508 675 Total current liabilitie	Current assets				
Inventories 714 765 Deferred income taxes 121 118 Other assets 110 33 Total current assets 2,902 3,561 Noncurrent assets 2,902 3,561 Property, plant and equipment 2,163 2,414 Cost 4,061 4,275 Accumulated depreciation 1,898 1,861 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total noncurrent assets 503 510 Current liabilities 500 674 Accrued expenses and other liabilities 508 675 Total current liabilities 508 675 Total current liabilities 508 675	Cash and cash equivalents	\$	911	\$	1,393
Deferred income taxes 121 118 Other assets 110 83 Total current assets 2,902 3,561 Noncurrent assets 4,061 4,275 Accumulated depreciation 1,898 1,861 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total assets 501 510 Val assets 501 501 Val assets 500 675 Total assets 500 675 Total current liabilities 508 675 Total current liabilities 1,250 1,687 Noncurrent liabilities 1,250 1,687 Noncurrent liabilities 677 701 Long-term debt	Accounts receivable		1,046		1,202
Other assets 110 83 Total current assets 2,902 3,561 Noncurrent assets 4,061 4,275 Accumulated depreciation 1,898 1,861 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 133 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total noncurrent assets 501 510 Current liabilities 500 674 Accrued expenses and other liabilities 508 675 Total and other payables 1,250 1,687 Noncurrent liabilities 1,250 1,687 Noncurrent liabilities 2,943 2,942 Employee benefit obligations 1,415 1,468 Asbestos lingation reserve 677 701 Deferred income taxes 51	Inventories		714		765
Total current assets 2,902 3,561 Noncurrent assets Property, plant and equipment 4,061 4,275 Accumulated depreciation 1,898 1,861 2,444 Goodwill 2,463 2,444 Goodwill 2,463 2,444 Goodwill 2,463 2,444 Goodwill 2,460 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Abbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total assets 501 510 Current liabilities 508 6.894 Current portion of long-term debt 9 9 Current liabilities 500 674 Accorde expenses and other liabilities 1,250 1,687 Noncurrent liabilities 1,250 1,687 Noncurrent liabilities 61 110 Long-term debt 2,943	Deferred income taxes		121		118
Total current assets 2,902 3,561 Noncurrent assets Property, plant and equipment 4,061 4,275 Accumulated depreciation 1,898 1,861 2,444 Goodwill 2,463 2,444 Goodwill 2,463 2,444 Goodwill 2,463 2,444 Goodwill 2,460 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Abbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total assets 501 510 Current liabilities 508 6.894 Current portion of long-term debt 9 9 Current liabilities 500 674 Accorde expenses and other liabilities 1,250 1,687 Noncurrent liabilities 1,250 1,687 Noncurrent liabilities 61 110 Long-term debt 2,943	Other assets		110		83
Property, plant and equipment 4,061 4,275 Accumulated depreciation 1,886 1,881 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total noncurrent assets 501 510 Total assets \$ 9,796 \$ 10,951 LIABILITIES AND STOCKHOLDERS' EQUITY \$ 233 \$ 329 Current liabilities \$ 0,061 441 Short-term debt \$ 9 9 Total and other payables 500 675 Total current liabilities 1,250 1,687 Noncurrent liabilities 1,250 1,687 Noncurrent liabilities 2,943 2,942 Employee benefit obligations 1,415 1,488 Asbestos litigation reserve 677 701 Deferred income taxes 51	Total current assets				
Cost 4,061 4,275 Accumulated depreciation 1,898 1,861 Net property, plant and equipment 2,163 2,414 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total noncurrent assets 6,894 7,390 Total assets \$ 9,796 \$ 10,951 Current liabilities \$ 500 674 Accrued expenses and other liabilities 508 675 Total current liabilities 508 675 Total current liabilities 500 674 Accrue expenses and other liabilities 508 675 Total current liabilities 508 675 Long-term debt 2,943 2,942 Employee benefit obligations 1,415 1,468 Asbestos litigation reserve 677 <td>Noncurrent assets</td> <td></td> <td></td> <td></td> <td></td>	Noncurrent assets				
Accumulated depreciation 1,898 1,861 Net property, plant and equipment 2,163 2,144 Goodwill 2,480 2,643 Intangibles 1,188 1,309 Restricted investments 300 - Asbestos insurance receivable 193 433 Equity and other unconsolidated investments 69 81 Other assets 501 510 Total noncurrent assets 501 510 Current liabilities \$ 9,796 \$ 10,951 Short-term debt 9 9 Current liabilities 500 674 Accrued expenses and other liabilities 508 675 Total current liabilities 508 675 Total current liabilities 1,250 1,687 Noncurrent liabilities 2,943 2,942 Employee benefit obligations 1,415 1,468 Asbestos litigation reserve 677 701 Deferred income taxes 51 100 Other liabilities 441	Property, plant and equipment				
Net property, plant and equipment2,1632,414Goodwill2,4602,643Intangibles1,1881,309Restricted investments300-Asbestos insurance receivable193433Equity and other unconsolidated investments6981Other assets501510Total noncurrent assets501510Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITY\$ 233\$ 329Current liabilities\$ 00674Short-term debt99Current portion of long-term debt508675Total accrued expenses and other liabilities508675Total current liabilities508675Total current liabilities1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities5,5275,681Stockholders' equity3,0193,583	Cost		4,061		4,275
Goodwill2,4802,643Intangibles1,1881,309Restricted investments300-Asbestos insurance receivable193433Equity and other unconsolidated investments6981Other assets501510Total noncurrent assets6,8947,390Total assets9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITY\$233\$ 329Current liabilities\$99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441466Total noncurrent liabilities51110Other liabilities515,527Stockholders' equity3,0193,583	Accumulated depreciation		1,898		1,861
Intangibles1,1881,309Restricted investments300-Asbestos insurance receivable193433Equity and other unconsolidated investments6981Other assets 501 510 Total noncurrent assets $6,894$ $7,390$ Total assets $$9,796$ \$10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities $$9,796$ \$10,951Short-term debt999Current portion of long-term debt999Accrued expenses and other liabilities 508 675 Total current liabilities $1,250$ $1,687$ Noncurrent liabilities $2,943$ $2,942$ Employee benefit obligations $1,415$ $1,468$ Asbestos litigation reserve 677 701 Deferred income taxes 51 110 Other liabilities $5,527$ $5,681$ Stockholders' equity $3,019$ $3,583$	·		2,163		
Restricted investments300Asbestos insurance receivable193Equity and other unconsolidated investments6981Other assetsTotal noncurrent assets6,8947,390Total assets6,8947,390Total assets6,894Short-term debt9999999997 total assets500674500Accrued expenses and other liabilitiesTotal current liabilities1,2501,687Noncurrent liabilitiesLong-term debt2,9432,9432,9432,9432,9432,9432,9432,9432,9432,944Employee benefit obligations1,4151,4151,4151,4151,4168Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5155275,681Stockholders' equity3,0193,583	Goodwill		2,480		2,643
Asbestos insurance receivable193433Equity and other unconsolidated investments6981Other assets501510Total noncurrent assets6,8947,390Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Intangibles		1,188		1,309
Equity and other unconsolidated investments6981Other assets501510Total noncurrent assets6,8947,390Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Restricted investments		300		-
Other assets501510Total noncurrent assets6,8947,390Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Short-term debt99Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities508675Noncurrent liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Asbestos insurance receivable		193		433
Total noncurrent assets6,8947,390Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Current portion of long-term debt\$ 233\$ 329Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities5,5275,681Stockholders' equity3,0193,583	Equity and other unconsolidated investments		69		81
Total noncurrent assets6,8947,390Total assets\$ 9,796\$ 10,951LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Current portion of long-term debt\$ 233\$ 329Current portion of long-term debt9 99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities5,5275,681Stockholders' equity3,0193,583			501		510
LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 233\$ 329Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Total noncurrent assets		6,894		
Current liabilities\$ 233\$ 329Short-term debt99Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Total assets	<u>\$</u>	9,796	\$	10,951
Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583					
Current portion of long-term debt99Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Short-term debt	\$	233	\$	329
Trade and other payables500674Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583				•	
Accrued expenses and other liabilities508675Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Long-term debt2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583			500		
Total current liabilities1,2501,687Noncurrent liabilities2,9432,942Long-term debt2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583					
Long-term debt2,9432,942Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583					
Employee benefit obligations1,4151,468Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Noncurrent liabilities				
Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Long-term debt		2,943		2,942
Asbestos litigation reserve677701Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	-				1,468
Deferred income taxes51110Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583					
Other liabilities441460Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583					
Total noncurrent liabilities5,5275,681Stockholders' equity3,0193,583	Other liabilities		441		460
Total liabilities and stockholders' equity <u>\$ 9,796</u> <u>\$ 10,951</u>	Stockholders' equity		3,019		3,583
	Total liabilities and stockholders' equity	\$	9,796	\$	10,951

Ashland Inc. and Consolidated Subsidiaries **STATEMENTS OF CONSOLIDATED CASH FLOWS**

(In millions - preliminary and unaudited)

(In millions - preliminary and unaudited)	Three months ended March 31				nded			
		2015		2014		2015		2014
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES								
FROM CONTINUING OPERATIONS	•		•		•		•	~~
Net income (loss) Income from discontinued operations (net of taxes)	\$	224 (129)	\$	(44) (17)	\$	257 (121)	\$	66 (39)
Adjustments to reconcile income from continuing operations to		(129)		(17)		(121)		(39)
cash flows from operating activities								
Depreciation and amortization		85		95		170		183
Debt issuance cost amortization		4		3		7		7
Purchased in-process research and development impairment		-		9		- (12)		9
Deferred income taxes Equity income from affiliates		(3) (4)		(1) (7)		(13) (7)		(4) (14)
Distributions from equity affiliates		(-)		(7)		10		6
Stock based compensation expense		8		9		15		17
Net loss (gain) on divestitures		33		(1)		118		(6)
Impairment of equity investments		14		46		14		46
Losses on pension plan remeasurements		9		105		9		105
Change in operating assets and liabilities (a) Total cash provided by operating activities from continuing operations		(201) 47		(22) 175		(363) 96		(182) 194
		47		175		90		194
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES								
FROM CONTINUING OPERATIONS		(43)		(51)		(96)		(06)
Additions to property, plant and equipment Proceeds from disposal of property, plant and equipment		(43)		(51) 4		(86) 1		(96) 4
Purchase of operatons - net of cash acquired		-		(2)		-		(2)
Proceeds from sale of operations or equity investments		-		1		106		6
Funds restricted for specific transactions		(320)		-		(320)		-
Total cash used by investing activities from continuing operations		(363)		(48)		(299)		(88)
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS								
Repayment of long-term debt		-		-		-		(12)
Proceeds (repayment) from short-term debt		(90)		87		(96)		93
Repurchase of common stock		(270)		-		(397)		-
Cash dividends paid		(23)		(26)		(46)		(53)
Excess tax benefits related to share-based payments		5		3		7		7
Total cash provided (used) by financing activities from continuing operations		(378)		64		(532)		35
CASH PROVIDED (USED) BY CONTINUING OPERATIONS		(694)		191		(735)		141
Cash provided (used) by discontinued operations Operating cash flows		361		13		277		20
Investing cash flows		12		(9)		10		(15)
Effect of currency exchange rate changes on cash and		12		(3)		10		(13)
cash equivalents		(24)		1		(34)		(1)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(345)		196		(482)		145
Cash and cash equivalents - beginning of period		1,256		295		1,393		346
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$	911	\$	491	\$	911	\$	491
DEPRECIATION AND AMORTIZATION								
Specialty Ingredients	\$	61	\$	60	\$	121	\$	120
Performance Materials	Ψ	14	Ψ	25	Ψ	30	Ψ	44
Valvoline		10		9		19		17
Unallocated and other		-		1		-		2
	\$	85	\$	95	\$	170	\$	183
ADDITIONS TO PROPERTY, PLANT AND EQUIPMENT	•	~~	¢	~~	^		¢	
Specialty Ingredients	\$	28	\$	33	\$	51	\$	62
Performance Materials Valvoline		4 8		6 7		10 18		13 13
Unallocated and other		о З		7 5		7		8
	\$	43	\$	51	\$	86	\$	96
(a) Excludes changes resulting from operations acquired or sold.	<u> </u>	-	<u> </u>		<u> </u>	-	<u> </u>	-

(a) Excludes changes resulting from operations acquired or sold.

Ashland Inc. and Consolidated Subsidiaries INFORMATION BY INDUSTRY SEGMENT

(In millions - preliminary and unaudited)

	Three months ended March 31					Six mont Marc		
	2015		2014		014 2015			2014
SPECIALTY INGREDIENTS								
Sales per shipping day	\$	9.3	\$	10.0	\$	9.2	\$	9.7
Metric tons sold (thousands)		82.7		87.4		162.6		169.1
Gross profit as a percent of sales (a)		31.7%		32.6%		32.2%		31.8%
PERFORMANCE MATERIALS								
Sales per shipping day	\$	4.5	\$	6.6	\$	5.0	\$	6.2
Metric tons sold (thousands)		118.3		153.4		247.8		291.3
Gross profit as a percent of sales (a)		22.7%		10.7%		19.8%		12.0%
VALVOLINE								
Lubricant sales (gallons)		40.5		39.6		79.5		78.2
Premium lubricants (percent of U.S. branded volumes)		40.7%		37.1%		39.6%		36.4%
Gross profit as a percent of sales (a)		36.1%	32.1%		34.7%		31.6%	

(a) Gross profit as a percent of sales is defined as sales, less cost of sales divided by sales.

Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - INCOME (LOSS) FROM CONTINUING OPERATIONS

(In millions - preliminary and unaudited)

Specialty Performance Unalocated Ingredients Materials Valvoline & Other Tax indemnity income 5 (18) 5 - \$ \$ Tax indemnity income - - 16 16 Impairment of equity investment - - (14) - (14) All other operating income 83 30 96 9 218 Operating income 83 30 96 9 218 NET INTEREST AND OTHER FINANCING EXPENSE 40 40 NET LOSS ON DIVESTITURES (15) (15) INCOME (LOSS) FROM CONTINUING OPERATIONS 5 65 30 5 32 35 Income tax expense (15) (15) (16) 25 25 Income (LOSS) FROM CONTINUING OPERATIONS 5 65 30 5 82 5 35 OPERATING INCOME (LOSS) Restructuring 1 1 1 1 1 1 1		Three Months Ended March 31, 2015											
OPERATING INCOME (LOSS) Image: measurement is indemnity income S (18) S S S S (18) S S S (18) S S S (18) S S S S S (14) - (16) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (15) (16) (15) (16) (15) (16) (16) (16) (16) (16) (16) (16) (16) (16)		1 2			1								
Restructuring \$ (16) \$		Ingre	dients	Ma	terials	Val	voline	&	Other		Total		
Tax indemnty income - - - 16 16 Losses on pension plan remeasurement - - - (14) - (9) (9) Impairment of equity investment - - - (14) - (14) - (14) All other operating income 83 30 36 9 218 Operating income 83 30 36 9 218 INCOME TAX EXPENSE (BENEFIT) (33) (33) (33) INCOME (LOSS) FROM CONTINUING OPERATIONS 5 5 30 5 2 25 205 INCOME (LOSS) FRestructuring (15) (15) (15) (15) (16) Inpairment of ASK joint venture Ingredients Valvoline Unaliocated Valvoline Valvoline 1 1 Inpairment of ASK joint venture - - - (9) - - (9) - - (9) - - (9) 1 1 1 1 1 1 1 1 1 1		•	(10)	•		•		•		•	(4.0)		
Losses on pension plan remeasurement - - - (9) (9) Impairment of equity investment - - - (14) - (14) All other operating income 65 30 82 16 193 NET INTEREST AND OTHER FINANCING EXPENSE 40 40 NET LOSS ON DIVESTITURES (33) (33) INCOME TAX EXPENSE (BENEFIT) (40) 40 Key items (15) (15) All other income tax expense (16) 25 INCOME (LOSS) FROM CONTINUING OPERATIONS 5 65 30 5 25 Speciality Performance Unallocated 40 40 OPERATING INCOME (LOSS) \$ - \$ (20) \$ - (67) \$ (67) Restructuring \$ - \$ (20) \$ - (46) Inpairment of PRAD assets (9) - - - (9) - - (46) Losses on pension pl		\$	(18)	\$	-	\$	-	\$	-	\$			
Impairment of equily investment -	•		-		-		-						
All other operating income 83 30 96 9 218 Operating income 65 30 82 16 193 NET INTEREST AND OTHER FINANCING EXPENSE 40 40 NET LOSS ON DIVESTITURES (33) (33) INCOME TAX EXPENSE (BENEFIT) (33) (33) (33) Key items (15) (15) (15) (15) All other income tax expense (15) (15) (15) (15) INCOME (LOSS) FROM CONTINUING OPERATIONS S 65 30 3 82 2 2 5 VEX.NUM Qualicotated Materials Valvoline Materials Valvoline & 000 (87) (87) Restructuring income (LOSS) Restructuring income (LOSS) \$ (67) \$ (87) \$ (87) All other operating income (loss) \$ \$ \$ \$ (10) (10) (10) (10) Operating income (loss) \$ \$ \$ \$ \$ (10) (11) (164) Deprating income (loss) \$<			-		-		- (14)						
Operating income 65 30 82 16 193 NET INTEREST AND OTHER FINANCING EXPENSE 40 40 40 NET LOSS ON DIVESTITURES (33) (33) (33) INCOME TAX EXPENSE (BENEFIT) Key items All other income tax expense (15) (15) 40 INCOME (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$ 82 \$ (15) 40 INCOME (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$ 82 \$ 95 Income (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$ 82 \$ \$ 95 Income (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$			83		- 30								
NET INTEREST AND OTHER FINANCING EXPENSE4040NET LOSS ON DIVESTITURES(33)(33)INCOME TAX EXPENSE (BENEFIT) Key items All other income tax expense(15)(15)INCOME (LOSS) FROM CONTINUING OPERATIONS $\overline{3 \ 65}$ $\overline{30}$ $\overline{3 \ 82}$ $\overline{5 \ (82)}$ DECRATING INCOME (LOSS) Restructuring Impairment of ASK joint venture Impairment of IPR2D assets Operating income (IGSS) $\overline{100}$ $\overline{100}$ $\overline{100}$ OPERATING INCOME (LOSS) Restructuring Impairment of ASK joint venture 													
NET LOSS ON DIVESTITURES(33)(33)INCOME TAX EXPENSE (BENEFIT) Key items(15)(15)All other income tax expense $\frac{40}{40}$ $\frac{40}{25}$ INCOME (LOSS) FROM CONTINUING OPERATIONS $$ 65$ $$ 30$ $$ 82$ $$ (82)$ SpecialtyFormance MaterialsUnallocated & OtherTotalOPERATING INCOME (LOSS) Restructuring Impairment of IRRD assets $$ (20)$ $$ - $ (67)$ $$ (67)$ Net ring income (LOSS) All other operating income (loss) $$ - $ (20)$ $$ - $ (105)$ (105)All other operating income (loss) $7 - $ - $ (105)$ (105)(105)All other operating income (loss) $7 - $ - $ - $ (105)$ (105)(105)All other operating income (loss) $7 - $ - $ - $ - $ (105)$ (105)(105)All other speciality $1 - $ 1 - $$			00		00		02		10		100		
INCOME TAX EXPENSE (BENEFIT) Key items All other income tax expense(15)(162)2Three Months Ended March 31, 2014SpeciallyPerformanceUnallocatedIngredientsNaterialsValvoline& Colspan="2">Colspan="2">Colspan="2"OPERATING INCOME (LOSS)Restructuring\$ (20)\$ -\$ (67)\$ (87)IngredientsValvoline& Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2">Colspan="2"(15)(16)IngredientsNaterialsValvoline& Colspan="2"OPERATING INCOME (LOSS)SColspan="2" <th <="" colspan="2" td=""><td>NET INTEREST AND OTHER FINANCING EXPENSE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>40</td><td></td><td>40</td></th>	<td>NET INTEREST AND OTHER FINANCING EXPENSE</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>40</td> <td></td> <td>40</td>		NET INTEREST AND OTHER FINANCING EXPENSE								40		40
Key items (15) (15) All other income tax expense 40 40 INCOME (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$ 82 \$ 82 \$ 95 Three Months Ended March 31, 2014 Speciality Performance Unallocated Impedients Materials Valvoline & Other Total OPERATING INCOME (LOSS) Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of IPR&D assets (9) - - (46) - - (9) Losses on pension plan remeasurements - (105) (105) (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 61 (35) 81 (171) (64) NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) (80) (80) Key items 22 22	NET LOSS ON DIVESTITURES								(33)		(33)		
Key items (15) (15) All other income tax expense 40 40 INCOME (LOSS) FROM CONTINUING OPERATIONS \$ 65 \$ 30 \$ 82 \$ 82 \$ 95 Three Months Ended March 31, 2014 Speciality Performance Unallocated Impedients Materials Valvoline & Other Total OPERATING INCOME (LOSS) Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of IPR&D assets (9) - - (46) - - (9) Losses on pension plan remeasurements - (105) (105) (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 61 (35) 81 (171) (64) NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) (80) (80) Key items 22 22	INCOME TAX EXPENSE (BENEFIT)												
All other income tax expense 40 25 40 25 INCOME (LOSS) FROM CONTINUING OPERATIONS $$ 65$ $$ 30$ $$ 82$ $$ (82)$ $$ 95$ Three Months Ended March 31, 2014Speciality IngredientsPerformance MaterialsUnallocated & OtherTotalOPERATING INCOME (LOSS) Restructuring Impairment of ASK joint venture Impairment of IPR&D assets $$ (20)$ $$ $ (67)$ $$ (87)$ Operating income Operating income Operating income Operating income (loss) $$ $ (20)$ $$ $ (46)$ NET INTEREST AND OTHER FINANCING EXPENSE $$ $ $ (105)$ $$ (105)$ Net GAIN ON DIVESTITURES $$ 1$ $$ 1$ $$ 1$ INCOME TAX EXPENSE (BENEFIT) Key items All other income tax expense $$ (80)$ $$ (80)$ All other income tax expense $$ (80)$ $$ (80)$ $$ (80)$									(15)		(15)		
INCOME (LOSS) FROM CONTINUING OPERATIONS Image: Second	•												
Three Months Ended March 31, 2014 Specialty Performance Unallocated Ingredients Materials Valvoline & Other Total OPERATING INCOME (LOSS) Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of JR&D assets (9) - - (46) - - (46) Losses on pension plan remeasurements - - (105) (105) (105) (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 61 (35) 81 (171) (64) NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) (80) (80) Key items 22 22 22 22 22 22 All other income tax expense 22 (43) (43) (43)											25		
Specialty IngredientsPerformance MaterialsUnallocated & OtherOPERATING INCOME (LOSS) Restructuring Impairment of ASK joint venture Impairment of IPR&D assets\$ - \$ (20) \$ - \$ (67) \$ (87) - (46) (105) (105) (105) (105) All other operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE the state of the state	INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	65	\$	30	\$	82	\$	(82)	\$	95		
Specialty IngredientsPerformance MaterialsUnallocated & OtherOPERATING INCOME (LOSS) Restructuring Impairment of ASK joint venture Impairment of IPR&D assets\$ - \$ (20) \$ - \$ (67) \$ (87) - (46) (9) (105) (105) (105) All other operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE the state of the state of th													
IngredientsMaterialsValvoline& OtherTotalOPERATING INCOME (LOSS) Restructuring Impairment of ASK joint venture Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss)\$-\$\$(67)\$(87)All other operating income Operating income (loss)(46)(46)NET INTEREST AND OTHER FINANCING EXPENSE(105)(105)NET GAIN ON DIVESTITURES11INCOME TAX EXPENSE (BENEFIT) Key items Discrete items All other income tax expense(80)(80)1515All other income tax expense2222(43)22(43)22(43)													
OPERATING INCOME (LOSS) Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of ASK joint venture - (46) (46) Impairment of IPR&D assets (9) (9) Losses on pension plan remeasurements (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 61 (35) 81 (171) (64) NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) 15 15 Key items 15 15 15 15 15 All other income tax expense 22 22 22 22						nths En	ded Marc						
Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of ASK joint venture - (46) - (46) Impairment of IPR&D assets (9) - (46) Losses on pension plan remeasurements (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 70 31 81 1 183 NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) (80) Liscrete items 1 15 15 All other income tax expense 22 22 22		•	•	Perfo	ormance			Una	llocated				
Restructuring \$ - \$ (20) \$ - \$ (67) \$ (87) Impairment of ASK joint venture - (46) - (46) Impairment of IPR&D assets (9) - (46) Losses on pension plan remeasurements (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 70 31 81 1 183 NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (80) (80) (80) Liscrete items 1 15 15 All other income tax expense 22 22 22		•	•	Perfo	ormance			Una	llocated		Total		
Impairment of ASK joint venture - (46) - - (46) Impairment of IPR&D assets (9) - - (9) Losses on pension plan remeasurements - - (105) (105) All other operating income 70 31 81 1 183 Operating income (loss) 61 (35) 81 (171) (64) NET INTEREST AND OTHER FINANCING EXPENSE 41 41 41 NET GAIN ON DIVESTITURES 1 1 1 INCOME TAX EXPENSE (BENEFIT) (800) (800) (80) Key items 15 15 15 15 All other income tax expense 22 22 22 22	OPERATING INCOME (LOSS)	•	•	Perfo	ormance			Una	llocated		Total		
Impairment of IPR&D assets(9)(9)Losses on pension plan remeasurements(105)(105)All other operating income7031811183Operating income (loss)61(35)81(171)(64)NET INTEREST AND OTHER FINANCING EXPENSE414141NET GAIN ON DIVESTITURES111INCOME TAX EXPENSE (BENEFIT) Key items Discrete items All other income tax expense(80)(80)All other income tax expense2222(43)(43)		Ingre	•	Perfo Ma	ormance terials	Val		Una &	llocated Other				
Losses on pension plan remeasurements(105)(105)All other operating income7031811183Operating income (loss)61(35)81(171)(64)NET INTEREST AND OTHER FINANCING EXPENSE414141NET GAIN ON DIVESTITURES111INCOME TAX EXPENSE (BENEFIT)111Key items151515All other income tax expense2222(43)(43)(43)	Restructuring	Ingre	•	Perfo Ma	ormance terials (20)	Val		Una &	llocated Other		(87)		
Operating income (loss)61(35)81(171)(64)NET INTEREST AND OTHER FINANCING EXPENSE414141NET GAIN ON DIVESTITURES111INCOME TAX EXPENSE (BENEFIT) Key items Discrete items All other income tax expense(80)(80)Discrete items (43)1515Operating income tax expense16171	Restructuring Impairment of ASK joint venture	Ingre	-	Perfo Ma	ormance terials (20) (46)	Val		Una &	llocated Other		(87) (46)		
NET INTEREST AND OTHER FINANCING EXPENSE4141NET GAIN ON DIVESTITURES11INCOME TAX EXPENSE (BENEFIT) Key items Discrete items All other income tax expense(80)(80) (80)2222(43)(43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets	Ingre	-	Perfo Ma	ormance terials (20) (46)	Val		Una &	llocated Other (67) -		(87) (46) (9)		
NET GAIN ON DIVESTITURES11INCOME TAX EXPENSE (BENEFIT) Key items Discrete items All other income tax expense(80) (80) (80) 15(80) (80) 15All other income tax expense22 (43)22 (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1		(87) (46) (9) (105)		
INCOME TAX EXPENSE (BENEFIT)(80)(80)Key items1515Discrete items1515All other income tax expense2222(43)(43)(43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1		(87) (46) (9) (105) 183		
Key items (80) (80) Discrete items 15 15 All other income tax expense 22 22 (43) (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss)	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) (67) - (105) 1 (171)		(87) (46) (9) (105) <u>183</u> (64)		
Key items (80) (80) Discrete items 15 15 All other income tax expense 22 22 (43) (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1 (171) 41		(87) (46) (9) (105) <u>183</u> (64) 41		
Discrete items 15 15 All other income tax expense 22 22 (43) (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE NET GAIN ON DIVESTITURES	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1 (171) 41		(87) (46) (9) (105) <u>183</u> (64) 41		
All other income tax expense 22 22 (43) (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE NET GAIN ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT)	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) (67) (105) <u>1</u> (171) 41 1		(87) (46) (9) (105) <u>183</u> (64) 41 1		
(43) (43)	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE NET GAIN ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Key items	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1 (171) 41 1 (80)		(87) (46) (9) (105) <u>183</u> (64) 41 1 (80)		
	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE NET GAIN ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Key items Discrete items	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1 (171) 41 1 (80) 15		(87) (46) (9) (105) <u>183</u> (64) 41 1 (80) 15		
	Restructuring Impairment of ASK joint venture Impairment of IPR&D assets Losses on pension plan remeasurements All other operating income Operating income (loss) NET INTEREST AND OTHER FINANCING EXPENSE NET GAIN ON DIVESTITURES INCOME TAX EXPENSE (BENEFIT) Key items Discrete items	Ingre	- - (9) - 70	Perfo Ma	(20) (46) - 31	Val	voline - - - 81	Una &	(67) - (105) 1 (171) 41 1 (80) 15 22		(87) (46) (9) (105) <u>183</u> (64) 41 1 (80) 15 22		

Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - FREE CASH FLOW

(In millions - preliminary and unaudited)

	Three months ended March 31					Six months endeo March 31				
Free cash flow (a)	2015		2014		2015		2014			
Total cash flows provided by operating activities										
from continuing operations	\$	47	\$	175	\$	96	\$	194		
Adjustments:										
Additions to property, plant and equipment		(43)		(51)		(86)		(96)		
Free cash flows	\$	4	\$	124	\$	10	\$	98		

(a) Free cash flow is defined as cash flows provided by operating activities less additions to property, plant and equipment and other items Ashland has deemed non operational (if applicable).

Ashland Inc. and Consolidated Subsidiaries **RECONCILIATION OF NON-GAAP DATA - ADJUSTED EBITDA** (In millions, proliminary and unaudited)

(In millions - preliminary and unaudited)

	Tł		onths ended rch 31			
Adjusted EBITDA - Ashland Inc.	2	2015	2	2014		
Net income (loss)	\$	224	\$	(44)		
Income tax expense (benefit)		25		(43)		
Net interest and other financing expense		40		41		
Depreciation and amortization (a)		83		88		
EBITDA		372		42		
Income from discontinued operations (net of taxes)		(129)		(17)		
Net loss on divestitures		33		-		
Operating key items (see Table 5)		25		247		
Adjusted EBITDA	\$	301	\$	272		
Adjusted EBITDA - Specialty Ingredients	•	05	•			
Operating income	\$	65	\$	61		
Add:						
Depreciation and amortization (a)		59		60		
Key items (see Table 5)	-	18	-	9		
Adjusted EBITDA	\$	142	\$	130		
Adjusted EBITDA - Performance Materials						
Operating income (loss)	\$	30	\$	(35)		
Add:	•			()		
Depreciation and amortization (a)		14		18		
Key items (see Table 5)		-		66		
Adjusted EBITDA	\$	44	\$	49		
	<u> </u>		Ŧ			
Adjusted EBITDA - Valvoline						
Operating income	\$	82	\$	81		
Add:						
Depreciation and amortization		10		9		
Key items (see Table 5)		14		-		
Adjusted EBITDA	\$	106	\$	90		

(a) Depreciation and amortization excludes accelerated depreciation of \$2 million for Specialty Ingredients and \$7 million for Performance Materials for the three months ended March 31, 2015 and 2014, respectively, which are displayed as key items within this table.